Skip to main navigation Skip to content

Wendy Chen MD Presents Aspirin for Breast Cancer (ABC) Trial at New ASCO Plenary Series Program

The Alliance for Clinical Trials in Oncology is pleased to announce that the Aspirin for Breast Cancer (ABC) trial led by Wendy Y. Chen, MD, MPH, of the Dana-Farber Cancer Institute, will be presented February 15, 2022, as part of the second American Society of Clinical Oncology Virtual Plenary Series.

The ABC Trial is a study to test whether aspirin will keep breast cancer from recurring and reduce death from breast cancer. It is the first U.S. study to try and answer this question. The ABC Trial is a randomized phase III trial studying how well aspirin works in preventing recurrence in patients with human epidermal growth factor receptor 2 (HER2) negative breast cancer after chemotherapy, surgery, and/or radiation therapy.

The ABC Trial met its accrual goal of 2,936 women and men nationwide between the ages of 18-70 diagnosed with node-positive breast cancer and closed to accrual on December 7, 2020.

The ASCO Plenary Series will feature a panel question and answer session with Dr. Chen and Angela DeMichele, MSCE, MD, of University of Pennsylvania, moderated by Erika P. Hamilton, MD, of Sarah Canon Research Institute and Tennessee Oncology, PLLC.

Join in to participate in the series here.

ClinicalTrials.gov Identifier: NCT02927249. A randomized phase III double-blinded placebo-controlled trial of aspirin as adjuvant therapy for HER2 negative breast cancer: The ABC trial (A011502)

Related Posts

Combo Extends OS in Patients 65+ with Ph+ ALL

Long-term results show combination treatment that skips chemotherapy is effective for older patients with Ph+ ALL

Model Predicts AI Non-adherence Risk

A new risk model uses baseline sociodemographic and financial measures to predict which patients prescribed long-term therapy with aromatase inhibitors for breast cancer are at significantly higher risk of stopping that therapy early

ECOG-ACRIN and PrECOG announce multiple presentations at ASH 2023

Researchers with the ECOG-ACRIN Cancer Research Group and PrECOG, LLC will present six oral and three poster presentations at the 65th American Society of Hematology Meeting & Exposition